Items where Funder is Sheffield Teaching Hospitals NHS Foundation Trust.

091002

Ji, X, Mukherjee, S, Landi, MT et al. (108 more authors) (2020) Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 11 (1). 2220.

Ji, X, Mukherjee, S, Landi, MT et al. (108 more authors) (2020) Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 11 (1). 2220.

161724; 181911

Rominiyi, O., Vanderlinden, A., Clenton, S.J. et al. (3 more authors) (2021) Tumour treating fields therapy for glioblastoma : current advances and future directions. British Journal of Cancer, 124. pp. 697-709. ISSN 0007-0920

C43420/A17904; C5410/A7315; C5410/A15588

Ji, X, Mukherjee, S, Landi, MT et al. (108 more authors) (2020) Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 11 (1). 2220.

C5410/A12152

Woll, P., Gaunt, P., Danson, S. et al. (8 more authors) (2022) Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP) : a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer, 171. pp. 26-33. ISSN 0169-5002

CA115

Ji, X, Mukherjee, S, Landi, MT et al. (108 more authors) (2020) Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 11 (1). 2220.

ECMC

Ji, X, Mukherjee, S, Landi, MT et al. (108 more authors) (2020) Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 11 (1). 2220.

N/A

Ji, X, Mukherjee, S, Landi, MT et al. (108 more authors) (2020) Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 11 (1). 2220.

Rominiyi, O., Vanderlinden, A., Clenton, S.J. et al. (3 more authors) (2021) Tumour treating fields therapy for glioblastoma : current advances and future directions. British Journal of Cancer, 124. pp. 697-709. ISSN 0007-0920

Rominiyi, O., Vanderlinden, A., Clenton, S.J. et al. (3 more authors) (2021) Tumour treating fields therapy for glioblastoma : current advances and future directions. British Journal of Cancer, 124. pp. 697-709. ISSN 0007-0920

STH18457

Pivonello, R., Fleseriu, M., Newell-Price, J. et al. (14 more authors) (2020) Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3) : a multicentre phase III study with a doubleblind, randomised withdrawal phase. The Lancet Diabetes & Endocrinology, 8 (9). pp. 748-761. ISSN 2213-8587

STH20030

Parker, W.A.E. orcid.org/0000-0002-7822-8852 and Storey, R.F. orcid.org/0000-0002-6677-6229 (2020) Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opinion on Emerging Drugs, 25 (1). pp. 1-6. ISSN 1472-8214

n/a

Woll, P., Gaunt, P., Danson, S. et al. (8 more authors) (2022) Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP) : a randomised, double-blind, placebo-controlled phase II trial. Lung Cancer, 171. pp. 26-33. ISSN 0169-5002